IL12/23 Blockade for Refractory Immune-Mediated Colitis: 2-Center Experience
Anusha Shirwaikar Thomas, Seung Eun Lee, Malek Shatila, Enrico N. De Toni, Helga‐Paula Török, Najib Ben Khaled, Nicholas Powell, Ryan Weight, David M. Faleck, Yinghong Wang
Abstract
INTRODUCTION: Immune checkpoint inhibitor-mediated colitis (IMC) is commonly managed with steroids and biologics. We evaluated the efficacy of ustekinumab (UST) in treating IMC refractory to steroids plus infliximab and/or vedolizumab. RESULTS: Nineteen patients were treated with UST for IMC refractory to steroids plus infliximab (57.9%) and/or vedolizumab (94.7%). Most of them had grade ≥3 diarrhea (84.2%), and colitis with ulceration was present in 42.1%. Thirteen patients (68.4%) attained clinical remission with UST, and mean fecal calprotectin levels dropped significantly after treatment (629 ± 101.5 mcg/mg to 92.0 ± 21.7 mcg/mg, P = 0.0004). DISCUSSION: UST is a promising therapy for the treatment of refractory IMC.